ArticleFrontiers in nutrition2026
Screening of risk factors and construction of a prediction model for enteral nutrition intolerance in elderly patients with comorbidities and sarcopenia.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To screen the independent risk factors for enteral nutrition intolerance (ENI) in elderly comorbid patients with sarcopenia, and to establish and validate a clinical prediction model for individualized risk assessment and targeted intervention. Methods: A total of 202 elderly comorbid patients with sarcopenia receiving enteral nutrition were retrospectively enrolled from the Geriatrics Department of Qingdao Municipal Hospital between January 2024 and December 2025. Patients were divided into ENI group ( Results: Severe dependence in activities of daily living (ADL) and concomitant psychiatric disorders were independently linked to higher ENI risk, whereas red blood cell (RBC) levels produced a protective effect. The predictive model delivered solid discriminative performance, registering an AUC of 0.77 (95% CI: 0.69-0.85) in the training cohort and 0.70 (95% CI: 0.57-0.84) in the validation cohort. The Hosmer-Lemeshow goodness-of-fit test confirmed adequate model calibration ( Conclusion: The developed nomogram exhibited acceptable discrimination and acceptable calibration upon internal validation, with detectable net clinical benefit. This visual risk scoring tool enables personalized ENI risk estimation in elderly multimorbid patients with sarcopenia. Additional multicenter external validation work should be finished prior to clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.